Meissa Vaccines’s MV-014-212, an intranasal recombinant live attenuated COVID-19 vaccine, induced mucosal and systemic antibodies against SARS-CoV-2 and two variants of concern.
From BioPharm International:
Meissa’s intranasal COVID-19 vaccine generated both mucosal and systemic antibodies in NHPs and was protective against wild-type SARS-CoV-2 challenge. The company also enrolled and dosed SARS-CoV-2 seronegative and seropositive adult participants in all dosage groups of a Phase I clinical trial of MV-014-212. Interim analysis of the trial data is expected later this year.
Read the full article here.